KDDF successfully holds 2025 KDDF Global Biotech Showcase

67 investors from 47 investment companies participated at the event, conducted over 400 one-on-one partnering sessions

Expanded CVC participation... raises expectations for joint and follow-up investments

2025 KDDF Global Biotech Showcase Group Photo

[The Korea Drug Development Fund (KDDF, CEO Yeong-Min Park) announced on the 27th that it will hold the '2025 KDDF Global Biotech Showcase' to attract overseas investment for excellent new drug candidates developed in Korea.

 

The showcase, which will be held over two days from May 27 to 28 at the Fairmont Ambassador Seoul Hotel, will focus on 1:1 partnering meetings with venture capitalists (VCs), where companies and investors will meet directly to discuss specific cooperation plans, to inject practical vitality into the domestic new drug development ecosystem.

 

Additionally, the event will focus on strengthening domestic pharmaceutical and biotech companies’ presence in the global market and accelerate new drug development through collaboration with investors.

 

Even in the current contracted global investment environment, it is crucial to provide domestic pharmaceutical and biotech companies with opportunities to connect with global investors and pharmaceutical firms through trusted platforms.

 

This approach lays the groundwork for overseas expansion and technology transfer while building trust through ongoing communication with investors.

 

The opening ceremony was attended by Chang-Yune Lee, 1st Vice Minister of Science and ICT, who expressed the government's high level of interest and support.

 

In his congratulatory address, Deputy Minister Lee said, “The Korean government recognizes the pharmaceutical and biotechnology industry as a core industry that will determine the future competitiveness of the country.

 

I expect today's event will serve as an important catalyst for the development of the industry.” Now in its third year, the event has seen a significant increase in participation from global VCs as well as domestic VCs and CVCs (corporate venture capital).

 

The event strategically expanded the investment value chain by structuring it to enable follow-on investment discussions that connect early-stage funding, commercialization, and entry into domestic and global markets.

 

A total of 67 investors, including global and domestic VCs and CVCs, will participate in various programs such as panel discussions, special lectures, roundtable meetings, and one-on-one partnering meetings.

 

Park said, “We anticipate that this event, where domestic and international investors gather in one place, will serve as a turning point for domestic new drug development companies and institutions to secure substantial investments.” He emphasized, “The KDDF will further strengthen its role as an industrial ecosystem platform that accelerates the Korean companies’ entry into the global market.” The participating global VC and CVC institutions are as follows: ▲AbbVie Inc.

 

▲Johnson & Johnson Innovation ▲Boehringer Ingelheim ▲Boehringer Ingelheim Venture Fund ▲Novo Holdings ▲ARCH Venture Partners ▲L illy Ventures) ▲Roche ▲Roche Accelerator ▲Solasta Ventures ▲YAFO Capital ▲Playground ▲Panacea Venture ▲Pivotal BioVenture Partners ▲Avidity Partners ▲DCI Partners (DCI Partners Co., Ltd.) ▲Mass General Brigham Innovation ▲Qiming Venture Partners ▲Humboldt fund ▲JLABS ▲Ascenta Capital ▲Astellas Venture ▲Lexington Partners.

 

Domestic VC/CVC participating institutions are as follows.

 

▲IMM Investment ▲Mirae Asset Capital ▲Partners Investment ▲Woori Venture Partners ▲Intervest ▲ Widwin Investment ▲KB Investment ▲CKD Venture Capital Inc ▲HLB Investment ▲Daewoong Investment ▲Scale Up Partners ▲LSK Investment Co., Ltd ▲Stonebridge Ventures ▲KB Securities ▲Kakao Ventures ▲ Korea Technology Finance Corporation ▲Samil PwC ▲Celltrion ▲SK Biopharm ▲LG Chem ▲Huons ▲Huons Global ▲GC Cell (Green Cross).